Morgan Stanley Arcellx, Inc. Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Arcellx, Inc. stock. As of the latest transaction made, Morgan Stanley holds 462,333 shares of ACLX stock, worth $30.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

462,333

Previous 618,117 25.2%

Holding current value

$30.1 Million

Previous $47.1 Million 35.57%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$60.26 - $79.13 $9.39 Million - $12.3 Million	-155,784 Reduced 25.2%	462,333 $30.3 Million
Q4 2024 Feb 14, 2025	SELL	$75.39 - $106.53 $10.5 Million - $14.8 Million	-139,035 Reduced 18.36%	618,117 $47.1 Million
Q3 2024 May 14, 2025	BUY	$50.91 - $86.61 $10.8 Million - $18.4 Million	212,075 Added 38.91%	757,152 $63.2 Million
Q3 2024 Nov 14, 2024	BUY	$50.91 - $86.61 $10.8 Million - $18.4 Million	212,075 Added 38.91%	757,152 $63.2 Million
Q2 2024 May 14, 2025	SELL	$49.74 - $66.98 $3.63 Million - $4.89 Million	-73,040 Reduced 11.82%	545,077 $30.1 Million
Q2 2024 Oct 17, 2024	SELL	$49.74 - $66.98 $7.54 Million - $10.2 Million	-151,685 Reduced 21.77%	545,077 $30.1 Million
Q2 2024 Aug 14, 2024	SELL	$49.74 - $66.98 $7.54 Million - $10.2 Million	-151,685 Reduced 21.77%	545,077 $30.1 Million
Q1 2024 Oct 17, 2024	BUY	$51.85 - $73.49 $7.86 Million - $11.1 Million	151,685 Added 27.83%	696,762 $48.5 Million
Q1 2024 Aug 16, 2024	BUY	$51.85 - $73.49 $1.22 Million - $1.73 Million	23,477 Added 3.49%	696,762 $48.5 Million
Q1 2024 May 15, 2024	BUY	$51.85 - $73.49 $1.22 Million - $1.73 Million	23,477 Added 3.49%	696,762 $48.5 Million
Q4 2023 Aug 16, 2024	BUY	$31.75 - $57.99 $4.07 Million - $7.43 Million	128,208 Added 23.52%	673,285 $37.4 Million
Q4 2023 Feb 13, 2024	BUY	$31.75 - $57.99 $18 Million - $32.9 Million	568,027 Added 539.65%	673,285 $37.4 Million
Q3 2023 Nov 15, 2023	SELL	$31.51 - $37.4 $5.48 Million - $6.5 Million	-173,853 Reduced 62.29%	105,258 $3.78 Million
Q2 2023 Aug 14, 2023	BUY	$27.49 - $46.9 $4.69 Million - $8.01 Million	170,713 Added 157.49%	279,111 $8.83 Million
Q1 2023 May 15, 2023	SELL	$26.92 - $33.94 $406,411 - $512,392	-15,097 Reduced 12.22%	108,398 $3.34 Million
Q4 2022 Feb 14, 2023	BUY	$17.18 - $33.0 $460,252 - $884,070	26,790 Added 27.7%	123,495 $3.83 Million
Q3 2022 Nov 14, 2022	BUY	$16.67 - $22.04 $326,098 - $431,146	19,562 Added 25.36%	96,705 $1.82 Million
Q2 2022 Oct 27, 2022	BUY	$7.21 - $24.43 $548,717 - $1.86 Million	76,105 Added 7331.89%	77,143 $1.4 Million
Q2 2022 Aug 15, 2022	BUY	$7.21 - $24.43 $548,717 - $1.86 Million	76,105 Added 7331.89%	77,143 $1.4 Million
Q1 2022 Oct 27, 2022	SELL	$12.97 - $19.14 $987,081 - $1.46 Million	-76,105 Reduced 98.65%	1,038 $14,000
Q1 2022 May 13, 2022	BUY	$12.97 - $19.14 $13,462 - $19,867	1,038 New	1,038 $14,000

Others Institutions Holding ACLX

# of Institutions

214

Shares Held

48.8M

Call Options Held

764K

Put Options Held

296K

View Full List

About Arcellx, Inc.

Ticker ACLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,819,200
Market Cap $2.85B
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...

More about ACLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account